Skip to content
Baret News – Lifestyle
Author:
Nxera Pharma
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
September 3, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer’s Cognition
August 26, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
August 7, 2026
Nxera Pharma Webinar for Financial Results Presentation – 2Q2026
July 15, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
June 30, 2026
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
June 10, 2026
Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
June 1, 2026
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026
May 26, 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
May 11, 2026
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
May 8, 2026
1
2
Next Page
→